Androgen Receptor LBD Protein: The Core Domain of Prostate Cancer Signaling Drive and Targeted Therapy

Author: Senior Product Manager of UA Views：6

This article focuses on the molecular characteristics and biological functions of the androgen receptor ligand-binding domain (AR-LBD), systematically elaborating its molecular mechanism as a member of the nuclear receptor superfamily in triggering conformational changes and activating transcription through androgen binding, analyzing the bidirectional structural communication between the AF2 hydrophobic surface and the ligand-binding pocket and its role in coactivator recruitment, and exploring the association of AR-LBD gene mutations with prostate cancer drug resistance and androgen insensitivity syndrome.

Recent Advances
Product Information

Recent Advances

Androgen Receptor LBD Protein: The Core Domain of Prostate Cancer Signaling and Targeted Therapy

Summary: This article focuses on the molecular characteristics and biological functions of the androgen receptor ligand-binding domain (AR-LBD), systematically elaborating its molecular mechanism as a member of the nuclear receptor superfamily in triggering conformational changes and activating transcription upon androgen binding, analyzing the bidirectional structural communication between the AF2 hydrophobic surface and the ligand-binding pocket and its role in coactivator recruitment, and discussing the association of AR-LBD gene mutations with prostate cancer drug resistance and androgen insensitivity syndrome.

I. Molecular Structural Features of AR-LBD and Its Positioning within the Nuclear Receptor Family.

The androgen receptor is a member of the steroid hormone receptor family, primarily mediating the physiological effects of androgens by binding to specific DNA sequences to influence the transcription of androgen-responsive genes. The AR protein comprises an N-terminal domain, a DNA-binding domain, a hinge region, and a C-terminal ligand-binding domain. The ligand-binding domain is the core structural module for AR signal regulation; its three-dimensional structure is similar to that of other steroid hormone receptors, and ligand binding induces conformational changes in the protein that enable coactivator molecules to bind, thereby amplifying hormone signals and mediating transcription initiation. AR-LBD has unique structural features within the nuclear receptor superfamily: unlike members such as the estrogen receptor that form obligate dimers, AR-LBD exists predominantly as a monomer in most resolved structures, and its dimerization interface has a distinctive "inside-out" configuration; this structural plasticity is the basis for understanding the complexity of AR functional regulation.

II. Ligand Recognition and Conformational Activation Mechanisms Mediated by AR-LBD.

The core function of AR-LBD lies in recognizing androgen ligands and initiating the transcriptional activation program. Upon binding of bioactive androgens such as testosterone and dihydrotestosterone to AR-LBD, helix 12 of activation function 2 (AF2) is stabilized, completing the assembly of the coactivator-binding surface. AF2 is a highly conserved hydrophobic surface formed by helices 3, 3', 4, and 12, flanked by clusters of oppositely charged residues. Ligand binding-induced conformational changes promote the formation of the AF2 surface, which in turn recruits SRC/p160 family coactivators containing LXXLL motifs; these factors possess histone acetyltransferase activity and initiate target gene transcription through chromatin remodeling. Notably, the affinity of AR AF2 for the LXXLL motif of coactivators is 5- to 10-fold weaker than its affinity for AR's own N-terminal FXXLF motif, and this difference makes the N-terminal/C-terminal interaction of AR occupy an important position in androgen-regulated gene expression.

III. Bidirectional Structural Communication between the Ligand-Binding Pocket and AF2.

A key structural feature of AR-LBD is the close spatial arrangement between the ligand-binding pocket and the AF2 coactivator-binding site. Beneath the surface of the AF2 coactivator-binding site, there exists a shallow interface adjacent to the ligand-binding pocket, and this tight structural arrangement provides a platform for communication between AF2 and the bound ligand. Evidence supporting structural communication in this boundary region comes from multiple sources: FXXLF motif binding to AF2 slows the androgen dissociation rate; binding of the coactivator LXXLL motif may also induce conformational changes in AF2 and affect ligand-binding kinetics. Molecular dynamics simulation studies have further revealed bidirectional communication pathways between the ligand-binding pocket and AF2: dihydrotestosterone binding promotes recruitment of the coactivator SRC3 to AF2, whereas antagonist binding induces AF2 shape perturbations and weakens its capacity to accommodate the LXXLL motif. This bidirectional structural relay mechanism determines the functional efficacy of AR in vivo and also explains why mutations in the AF2 region can alter AR transcriptional activity without affecting equilibrium androgen binding affinity.

activity.

IV. AR-LBD Mutations and Prostate Cancer Drug Resistance and Androgen Insensitivity Syndrome.

AR-LBD is a hotspot region for mutations associated with multiple diseases. More than 300 different AR single amino acid mutations or partial gene deletions can cause androgen insensitivity syndrome; partial loss of function causes male infertility and varying degrees of incomplete masculinization, while complete loss of function leads to a feminized external genitalia phenotype in genetic males. The frequency of AR gene mutations in the population is approximately 0.002%, and the vast majority of single-base changes are located in the highly structured ligand-binding domain. In prostate cancer, AR is a key mediator of disease occurrence and progression, providing prostate cancer cells with growth signals throughout the disease course. After advanced prostate cancer becomes unresponsive to hormone deprivation therapy, AR signaling is maintained through multiple molecular strategies. Although the second-generation antiandrogens enzalutamide and apalutamide have achieved significant clinical success, acquired resistance limits their benefit, and the F877L mutation can convert both drugs from antagonists to agonists. In response to resistance mutations targeting the ligand-binding pocket, researchers have proposed a new strategy of targeting the AR-LBD dimerization interface, characterized a pocket located at the dimerization interface, and developed first-in-class antagonists targeting this site.

V. Conclusion.

In basic research and drug development related to AR-LBD, high-quality recombinant AR-LBD protein is a core tool for elucidating its binding mechanisms with androgen ligands, evaluating coactivator recruitment efficiency, and screening targeted drugs. In response to the needs of AR-LBD functional research and prostate cancer targeted therapy development, Ulab provides ANDR(LBD) Protein, Human. This product is suitable for applications such as binding activity analysis of AR-LBD with ligands including testosterone and dihydrotestosterone, research on AF2-mediated recruitment of coactivator LXXLL motifs, mechanistic exploration of bidirectional structural communication between the ligand-binding pocket and AF2, and in vitro screening and evaluation of antagonists and degraders targeting AR-LBD.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Next